Karyopharm wins approval of bidding procedures with Ayrmid as stalking horse
The U.S. Bankruptcy Court for the Southern District of Texas granted the motion of Karyopharm Therapeutics Inc. and its debtor affiliate KPT Texas LLC on Nov. 3, 2026. The procedures cover a sale of all, substantially all or a material portion of the debtors' assets, including their rights to XPOVIO (selinexor). Ayrmid Ltd.'s bid, set out in the restructuring support agreement and plan, is deemed a qualified bid. If no other qualified bid arrives by the bid deadline, the debtors will proceed with the reorganization transaction under the plan. Bids are due Dec. 16, 2026 at 4:00 p.m. An auction, if applicable, is set for Dec. 21, 2026 at 10:00 a.m. The order sets the sale hearing for Jan. 11, 2027 at 9:00 a.m., and the bidding procedures make that hearing subject to the court's availability.